Ascendis Pharma A/S ASND
225.60
(5.10)
(2.21%)
as of 25 Sep
- Market cap
- $15.7B
- P/E
- 16.3×
Follow ASND
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
164.31% | 172.80% | 311.60% | 118.44% | |
| (19.99%) | (18.76%) | 33.40% | 44.34% | ||
ROIC |
(82.72%) | (91.65%) | (1.01%) | 15.07% | |
Return on Tangible Assets |
(164.00%) | (122.55%) | 375.74% | 69.94% | |
Average Days of Receivables |
86.95 | 79.93 | 84.24 | 78.46 | |
Free Cash Flow per Share |
(1.97) | 0.85 | 0.80 | 6.02 | |
Free Cash Flow |
(119.66) | 51.38 | 49.14 | 387.49 | |
Capital Expenditures |
(6.37) | (9.60) | (17.89) | (16.61) | |
Piotroski F-Score |
5.00 | 5.00 | 6.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
(8.22%) | 4.07% | 2.93% | 12.88% | |
Accounts Receivable Turnover |
6.35 | 4.40 | 6.41 | 6.09 | |
Accounts Payable Turnover |
1.09 | 1.04 | 1.21 | 0.93 | |
Inventory Turnover |
0.30 | 0.32 | 0.32 | 0.30 | |
Average Days of Payables |
351.91 | 348.63 | 306.79 | 416.48 | |
Days of Inventory on Hand |
1,352.22 | 1,159.56 | 1,227.11 | 1,244.71 | |
Tax Rate |
0.04 | 0.07 | (3.91) | 6.93 | |
Research and Development Expense of Revenue |
46.48% | 42.16% | 32.23% | 27.05% | |
Selling, General and Administrative Expense of Revenue |
61.85% | 63.58% | 58.33% | 54.53% | |
Share Based Compensation of Revenue |
17.71% | 16.13% | 14.05% | 11.39% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.44 | (0.24) | 0.12 | 0.47 | |
Depreciation/Fixed assets |
0.17 | 0.12 | 0.13 | 0.13 | |
Capex/Depreciation |
(0.32) | (0.48) | (0.89) | (0.82) | |
Revenue per Share |
11.89 | 13.44 | 16.16 | 18.84 | |
Operating CF per Share |
(1.86) | 1.01 | 1.09 | 6.28 | |
Capex per Share |
(0.10) | (0.16) | (0.29) | (0.26) | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.01 | |
Net Profit Margin |
(35.30%) | (31.67%) | 58.00% | 71.20% |
Columns are period end dates